Drugs for Dedifferentiated Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 30)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Doxorubicin |
Approved, Investigational |
Phase 2, Phase 3 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
ADM
ADR
Adriablastin
Adriablastine
Adriamycin
Adriamycin PFS
Adriamycin RDF
Adriamycin Semiquinone
Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride
Adriblastin
Adriblastina
Adriblastine
Adrimedac
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
Bristol-myers squibb brand OF doxorubicin hydrochloride
Caelyx
Cell pharm brand OF doxorubicin hydrochloride
Columbia brand OF doxorubicin hydrochloride
DM2
DOXIL
Doxo
Doxo cell
Doxo-cell
Doxolem
DOXORUBICIN
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
|
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
Elan brand OF doxorubicin hydrochloride
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
Hexal brand OF doxorubicin hydrochloride
Hydrochloride, doxorubicin
HYDROXYDAUNORUBICIN
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
Medac brand OF doxorubicin hydrochloride
Myocet
Neocorp brand OF doxorubicin hydrochloride
NSC-123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Tedec meiji brand OF doxorubicin hydrochloride
Urokit doxo cell
Urokit doxo-cell
VALRUBICIN IMPURITY, DOXORUBICIN
|
|
2 |
|
Anti-Bacterial Agents |
|
Phase 2, Phase 3 |
|
|
|
3 |
|
Antibiotics, Antitubercular |
|
Phase 2, Phase 3 |
|
|
|
4 |
|
Liposomal doxorubicin |
|
Phase 2, Phase 3 |
|
|
|
5 |
|
Coenzyme M |
Approved, Investigational |
Phase 2 |
|
3375-50-6 |
598 23662354 |
Synonyms:
1-THIOETHANEsulfonate
1-THIOETHANEsulfonIC ACID
1-THIOETHANEsulphonate
1-THIOETHANEsulphonic acid
2 Mercaptoethanesulfonate
2-Mercaptoethane
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
2-Mercaptoethanesulphonate
2-Mercaptoethanesulphonate, sodium
2-Mercaptoethanesulphonic acid
2-Mercaptoethylsulfonate
2-Mercaptoethylsulfonic acid
2-Mercaptoethylsulphonate
2-Mercaptoethylsulphonic acid
2-Sulfanylethylsulfonate
2-Sulfanylethylsulfonic acid
2-Sulphanylethylsulphonate
2-Sulphanylethylsulphonic acid
ASTA D 7093
ASTA medica brand OF mesna
ASTAD 7093
ASTA-D 7093
beta-Mercaptoethanesulfonate
beta-Mercaptoethanesulfonic acid
beta-Mercaptoethanesulphonate
beta-Mercaptoethanesulphonic acid
b-Mercaptoethanesulfonate
b-Mercaptoethanesulfonic acid
b-Mercaptoethanesulphonate
b-Mercaptoethanesulphonic acid
Bristol myers squibb brand OF mesna
|
Bristol-myers squibb brand OF mesna
Cell pharm brand OF mesna
Coenzima m
Coenzym m
Coenzyme m
CoM
D-7093
HS-CoM
Kendrick brand OF mesna
Mesna
MESNA cell
Mesna kendrick brand
Mesna sanfer brand
MESNA-cell
Mesnex
Mesnum
Mistabron
Mistabronco
Mitexan
Mucofluid
NSC-113891
Reduced coenzyme m
Reduced com
Sanfer brand OF mesna
Sodium 2-mercaptoethanesulphonate
UCB brand OF mesna
Uromitexan
Ziken
Î’-mercaptoethanesulfonate
Î’-mercaptoethanesulfonic acid
Î’-mercaptoethanesulphonate
Î’-mercaptoethanesulphonic acid
|
|
6 |
|
Ifosfamide |
Approved |
Phase 2 |
|
3778-73-2 |
3690 |
Synonyms:
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Asta Z 4942
Holoxan
Ifex
Ifosfamid
Ifosfamida
IFOSFAMIDE
Ifosfamide sterile
Ifosfamidum
Ifosphamide
Ifsofamide
Iphosphamid
|
Iphosphamide
I-phosphamide
Iso endoxan
Iso-endoxan
Isofosfamide
Isophosphamide
Isosfamide
MITOXANA
MJF-9325
NSC-109724
Z-4942
|
|
7 |
|
Durvalumab |
Approved, Investigational |
Phase 2 |
|
1428935-60-7 |
|
Synonyms:
|
8 |
|
Palbociclib |
Approved, Investigational |
Phase 2 |
|
571190-30-2 |
5330286 |
Synonyms:
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-D)pyrimidin-7-one
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-{[5-(PIPERAZIN-1-YL)PYRIDIN-2-YL]AMINO}PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
IBRANCE
Ibrance®|PD-0332991|PD0332991
PALBOCICLIB
|
PD 0332991
PD 332991
PD0332991
PD-0332991
UNII-g9Zf61le7g
|
|
9 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
10 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
11 |
|
Everolimus |
Approved |
Phase 2 |
|
159351-69-6 |
70789204 6442177 |
Synonyms:
001, RAD
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-HYDROXYETHYL)RAPAMYCIN
Afinitor
AFINITOR DISPERZ
Afinitor®|Certican®|RAD-001|RAD001|rapamycin, 42-O-(2-hydroxyethyl)-|Zortress®
Certican
EVEROLIMUS
évérolimus
RAD 001
|
RAD 666
RAD, SDZ
RAD001
RAD-001
RAD-666
SDZ RAD
SDZ-RAD
VOTUBIA
ZORTRESS
|
|
12 |
|
Sirolimus |
Approved, Investigational |
Phase 2 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Antibiotic ay 22989
AY-22989
AY-22989|Fyarro® (sirolimus albumin-bound particles)|Rapamune®|rapamycin|WY-090217
L04AA10
NSC-226080
Perceiva
RAPA
Rapammune
|
Rapamune
Rapamycin
Rapamysin
RPM
Sirolimus
Sirolimús
Sirolimusum
SM-88 COMPONENT SIROLIMUS
WY-090217
|
|
13 |
|
Trabectedin |
Approved, Investigational |
Phase 2 |
|
114899-77-3 |
108150 |
Synonyms:
Ect 743
Ecteinascidin
Ecteinascidin 743
ecteinascidin 743|ET-743|Yondelis®
ECTEINASCIDINS TRABECTEDIN
ET743
|
ET-743
NSC 684766
NSC-648766
Trabectedin
Trabectedina
Yondelis
|
|
14 |
|
Pioglitazone |
Approved, Investigational |
Phase 2 |
|
111025-46-8 |
4829 |
Synonyms:
(+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-{4-[2-(5-ETHYLPYRIDIN-2-YL)ETHOXY]BENZYL}-1,3-THIAZOLIDINE-2,4-DIONE
Actos
Actos®|Glustin®|pioglitazone HCl|U-72107A
Actost
AD-4833
DUETACT
Glustin
Pioglitazona
Pioglitazona [INN-Spanish]
|
PIOGLITAZONE
Pioglitazone [Ban:Inn]
Pioglitazone HCL
Pioglitazone hydrochloride
Pioglitazonum
Pioglitazonum [INN-Latin]
Poglitazone hydrochloride
U-72107
U-72107A
XAB907
ZACTOS
|
|
15 |
|
Palifosfamide |
Investigational |
Phase 2 |
|
31645-39-3 |
100427 |
Synonyms:
Ifosfamide mustard
Ifosforamide mustard
IPAM
Iphosphoramide mustard
IPM
Isophosphamide mustard
Isophosphoramide mustard
N,N'-BIS-(2-CHLOROETHYL)PHOSPHORIC ACID
|
N,N'-di-(2-chloroethyl)phosphorodiamidic acid
NN'-Bis-(2-chloroethyl)phosphate
NN'-Bis-(2-chloroethyl)phosphoric acid
NSC-297900
Palifosfamide
Palifosfamide-tris
ZIO-201
Zio-201isophosphamide mustard
|
|
16 |
|
Immunoglobulins, Intravenous |
|
Phase 2 |
|
|
|
17 |
|
Immunoglobulin G |
|
Phase 2 |
|
|
|
18 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
19 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
20 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
21 |
|
Antibodies |
|
Phase 2 |
|
|
|
22 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
23 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
24 |
|
Immune Checkpoint Inhibitors |
|
Phase 2 |
|
|
|
25 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
26 |
|
Alkylating Agents |
|
Phase 2 |
|
|
|
27 |
|
Antineoplastic Agents, Alkylating |
|
Phase 2 |
|
|
|
28 |
|
Hypoglycemic Agents |
|
Phase 2 |
|
|
|
29 |
|
Avelumab |
Approved, Investigational |
Phase 1 |
|
1537032-82-8 |
|
Synonyms:
AVELUMAB
BAVENCIO
MSB0010682
|
|
|
30 |
|
Poly I-C |
|
Phase 1 |
|
|
|
Interventional clinical trials:
(show all 26)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of BI 907828 Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma |
Recruiting |
NCT05218499 |
Phase 2, Phase 3 |
BI 907828;Doxorubicin |
2 |
SARC041: Phase 3 Randomized Double-Blind Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma |
Recruiting |
NCT04967521 |
Phase 3 |
Abemaciclib;Placebo |
3 |
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS) |
Active, not recruiting |
NCT02606461 |
Phase 2, Phase 3 |
Selinexor;Placebo |
4 |
A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients With Dedifferentiated Liposarcoma |
Active, not recruiting |
NCT04979442 |
Phase 3 |
RAIN-32;Trabectedin |
5 |
A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma |
Unknown status |
NCT02571829 |
Phase 2 |
ribociclib |
6 |
A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma |
Unknown status |
NCT03096912 |
Phase 2 |
Ribociclib |
7 |
Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall |
Unknown status |
NCT03651375 |
Phase 2 |
Sequential chemotherapy - 3 courses of AI |
8 |
Phase II Trial of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma |
Completed |
NCT01913652 |
Phase 2 |
Cabazitaxel |
9 |
A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma |
Completed |
NCT02247544 |
Phase 2 |
Trabectedin |
10 |
A Phase II Multi-Arm Study to Test the Efficacy of Oleclumab and Durvalumab in Multiple Sarcoma Subtypes |
Recruiting |
NCT04668300 |
Phase 2 |
|
11 |
A Phase II Study of CDK4/6 Inhibition (Palbociclib) Combined With PD-1 Blockade (INCMGA00012) in Patients With Advanced Well-differentiated Dedifferentiated Liposarcoma |
Recruiting |
NCT04438824 |
Phase 2 |
INCMGA00012;Palbociclib |
12 |
A Phase II Study, With a Safety lead-in, to Evaluate ATX-101, a Peptide Drug Targeting PCNA, in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma |
Recruiting |
NCT05116683 |
Phase 2 |
ATX-101 |
13 |
Phase II Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma |
Active, not recruiting |
NCT03307616 |
Phase 2 |
|
14 |
Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma |
Active, not recruiting |
NCT02500797 |
Phase 2 |
|
15 |
Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) |
Active, not recruiting |
NCT03114527 |
Phase 2 |
Ribociclib;Everolimus |
16 |
Phase 2 Study of Abemaciclib (LY2835219) in Dedifferentiated Liposarcoma |
Active, not recruiting |
NCT02846987 |
Phase 2 |
Abemaciclib |
17 |
Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas |
Active, not recruiting |
NCT03989596 |
Phase 2 |
|
18 |
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial of TQB3616 Capsules Versus Placebo in the Treatment of Dedifferentiated Liposarcoma |
Not yet recruiting |
NCT05496569 |
Phase 2 |
TQB3616 capsule;TQB3616 placebo |
19 |
A Phase 2 Multicenter, Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas |
Not yet recruiting |
NCT05580588 |
Phase 2 |
SPH4336 |
20 |
A Phase II Study on Trabectedin in Combination With PPARg Agonist Pioglitazone in Patients With Round Cell Myxoid Liposarcomas or Dedifferentiated G1 and G2 Liposarcomas With Stable Disease After a Monotherapy With Trabectedin. (TRABEPIO) |
Not yet recruiting |
NCT04794127 |
Phase 2 |
Trabectedin;Pioglitazone Oral Product |
21 |
Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial |
Terminated |
NCT01876043 |
Phase 2 |
plitidepsin |
22 |
A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma |
Withdrawn |
NCT00969917 |
Phase 2 |
IPI-504 |
23 |
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients With Advanced Solid Tumors |
Recruiting |
NCT03604783 |
Phase 1 |
TP-1287 |
24 |
A Phase 1b Dose Escalation and Dose Expansion Study of a CSF1R Inhibitor (DCC-3014) Administered Concurrently With an Anti-PD-L1 Antibody (Avelumab) in Patients With Advanced High-grade Sarcoma |
Active, not recruiting |
NCT04242238 |
Phase 1 |
DCC-3014;Avelumab |
25 |
A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma |
Active, not recruiting |
NCT04420975 |
Phase 1 |
|
26 |
Correlation of DDLS Grading to OCT, HRT, and HVF |
Completed |
NCT00430287 |
|
|
|